Statin Cessation Non-Inferior for Mortality in Primary Prevention Over 75

SAGA/SITE provides the first randomized evidence that stopping statins in adults 75 or older without atherosclerotic disease does not increase 3-year all-cause mortality, though imprecision limits the strength of the conclusion.

📅 Journal publication: Jul 2026 (online Aug 11, 2026) · Last updated: Oct 12, 2026

statinsatorvastatinsimvastatinpravastatinrosuvastatindeprescribingprimary preventionASCVDolder adultsgeriatricslipidsLDL cholesterolnon-inferiority RCTSAGASITEmortality Cardiology

Also in Geriatrics

Background Information

Can statins be safely discontinued in adults over 75?

Understanding the role of statins in older adults can impact prescribing practices and patient outcomes. The trial found that discontinuing statins in adults aged 75+ was non-inferior for preventing atherosclerotic cardiovascular disease (ASCVD) compared to continuing therapy. This suggests that discontinuation of statins in older adults for primary prevention may be a viable option, though patient-specific factors should be considered. Statin discontinuation in adults over 75 may not increase ASCVD risk.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Bonnet F, Poulizac P, Rousselot N, Couffinhal T, Galli G, Berdaï D, Vandenhende MA, Rousset M, Coueron R, Bénard A, Joseph JP, SAGA/SITE Study Group

Citation: Bonnet F, Poulizac P, Rousselot N, et al. Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial. The lancet. Healthy longevity. 2026;7(7):100884. doi:10.1016/j.lanhl.2026.100884

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →